CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+14.84%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.34B
AUM Growth
+$1.34B
(+1.6%)
Cap. Flow
-$68.7M
Cap. Flow
% of AUM
-5.12%
Top 10 Holdings %
Top 10 Hldgs %
67.96%
Holding
45
New
3
Increased
4
Reduced
16
Closed
3
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$33.1M |
| 2 |
Merus
MRUS
|
$20M |
| 3 |
Cabaletta Bio
CABA
|
$7.6M |
| 4 |
VYNE Therapeutics
VYNE
|
$2.26M |
| 5 |
Edgewise Therapeutics
EWTX
|
$1.97M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$17.3M |
| 2 |
Arcellx
ACLX
|
$16.5M |
| 3 |
Axsome Therapeutics
AXSM
|
$15.7M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$11.8M |
| 5 |
Janux Therapeutics
JANX
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $401M | 29.86% | 8,494,151 | – | – |
|
2
EyePoint Pharmaceuticals
EYPT
$797M
| $78.3M | 5.84% | 8,325,000 | – | – |
|
|
3
BridgeBio Pharma
BBIO
$9.89B
| $69.1M | 5.15% | 1,600,000 -400,000 | -20% | -$17.3M |
|
4
Praxis Precision Medicines
PRAX
$958M
| $68.3M | 5.09% | 1,625,000 -120,000 | -7% | -$5.05M |
|
|
5
Merus
MRUS
$4.98B
| $58.9M | 4.39% | 1,120,000 +380,000 | +51% | +$20M |
|
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $55.7M | 4.15% | 4,251,992 +150,000 | +4% | +$1.97M |
|
7
Insmed
INSM
$28.8B
| $54.3M | 4.05% | 540,000 +15,000 | +3% | +$1.51M |
|
|
8
Arcellx
ACLX
$3.85B
| $52.7M | 3.92% | 800,000 -250,000 | -24% | -$16.5M |
|
|
9
NewAmsterdam Pharma
NAMS
$2.71B
| $39.4M | 2.93% | 2,175,000 -650,000 | -23% | -$11.8M |
|
|
10
Janux Therapeutics
JANX
$1.37B
| $34.7M | 2.58% | 1,500,000 -500,000 | -25% | -$11.6M |
|
|
RAPP
11
Rapport Therapeutics
RAPP
$643M
| $33.4M | 2.49% | 2,940,921 | – | – |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $33.1M | 2.47% | +350,000 | New | +$33.1M |
|
|
BBOT
13
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $30.9M | 2.3% | 2,909,000 | – | – |
|
|
DRUG
14
Bright Minds Biosciences
DRUG
$276M
| $27.7M | 2.06% | 1,059,331 | – | – |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $27.4M | 2.04% | 2,086,600 -175,000 | -8% | -$2.3M |
|
16
Pharvaris
PHVS
$1.39B
| $25.6M | 1.91% | 1,454,660 -11,800 | -0.8% | -$208K |
|
17
GH Research
GHRS
$837M
| $24.5M | 1.82% | 2,009,482 | – | – |
|
18
ARS Pharmaceuticals
SPRY
$1.15B
| $19.2M | 1.43% | 1,100,000 -500,000 | -31% | -$8.73M |
|
19
Corbus Pharmaceuticals
CRBP
$115M
| $16.4M | 1.22% | 2,375,000 | – | – |
|
|
ABVX
20
Abivax
ABVX
$6.12B
| $16.3M | 1.21% | 2,130,000 | – | – |
|
21
CG Oncology
CGON
$2.04B
| $16.3M | 1.21% | 625,000 -150,000 | -19% | -$3.9M |
|
22
Arcutis Biotherapeutics
ARQT
$1.86B
| $14M | 1.04% | 1,000,000 -350,000 | -26% | -$4.91M |
|
|
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
| $13.9M | 1.04% | 3,381,277 | – | – |
|
24
Tarsus Pharmaceuticals
TARS
$2.47B
| $12.2M | 0.91% | 300,000 -100,000 | -25% | -$4.05M |
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| $11.5M | 0.86% | 400,000 -200,000 | -33% | -$5.75M |
|